Clinical Trial Update: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating subcutaneous daratumumab regimens in combination with bispecific T cell redirecting antibodies f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bispecific T cell redirecting antibody(s)
• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING